Page 16 of 19 · 454 questions tagged vendor-vetting.
Setup, so nobody has to ask: lot-specific certificate · JEEP. I have read the primary source rather than the summary, which has left me with more questions. I…
Setup, so nobody has to ask: 96.4% · cagrilintide · Homopeptide. I would like to set this up properly once, rather than adjust it repeatedly. My budget is real but…
This is a first order from this supplier, so I have no track record to reason from. This is a procedural question rather than a theoretical one, and I would like the…
The method section is present, which is unusual enough that I want to make use of it. I would like to know the limits of what can be inferred from this. What I am…
Conditions: 99.4% · liraglutide · BCH. I want to decide this in advance so that I am not deciding it under pressure later. Assume I will follow the plan I write down,…
The lot number on the vial matches the certificate, which at least rules out the easy problem. I have read the primary source rather than the summary, which has left…
Stated plainly: ERP · a GLP-1 receptor agonist. This is not behaving the way I expected and I want to understand the discrepancy before I act on it. I have…
Conditions: WXT · GL Biochem (Shanghai). Both of these get recommended confidently by different people, which suggests neither is obviously right. My constraints are…
Concretely: MKM · semaglutide. An unexpected observation, and I would like a differential rather than reassurance. The conditions were within what I understood to be…
What I have: 98.2% · orforglipron · SSA. This is a planning question. I know what my options are; I do not know how to weigh them. What I want is the minimum viable…
The specifics, since they change the answer: CPC · liraglutide. The claim is plausible, which is exactly why I want to check it. I am able to read a paper if someone…
The case in front of me: list of related substances · GGPeps. The figures are clear enough; the question is what they mean and what they do not. I can supply the…
The particulars: dulaglutide · batch certificate. I would like help reading this properly rather than being told what conclusion to reach. I have the full report…
The particulars: 96.4% · semaglutide · KP. I am at the decision point and I would rather think it through than improvise. I would rather spend money on measurement…
I have both a purity figure and a content figure, which is why the discrepancy is visible. I can parse the result. I am less sure what it licenses me to conclude. I…
Concretely: TFC · liraglutide. I think I have a problem. I am not yet sure whether it is a real problem or a measurement artefact. I want to know whether this is…
Numbers first: 97.6% · orforglipron · GL Biochem. This is a planning question. I know what my options are; I do not know how to weigh them. What I want is the minimum…
What I have: Medutest · ChinaPeptides (QYAOBIO). I would like help reading this properly rather than being told what conclusion to reach. I have the full report…
I have both a purity figure and a content figure, which is why the discrepancy is visible. This is presented as though it settles something, and I am not convinced it…
The lot number on the vial matches the certificate, which at least rules out the easy problem. The figures are clear enough; the question is what they mean and what…
Stated plainly: 96.4% · a GLP-1 receptor agonist · HJ. I would like to set this up properly once, rather than adjust it repeatedly. My budget is real but not tight,…
For reference: JEEP · dulaglutide. Before I write this off, I want to check whether it is a known failure mode. I have the lot number, the certificate and the date,…
I have certificates from two lots and an independent result on one of them. I want a method I can write down and repeat, not a rule of thumb. I would rather…
What I am working with: 98.2% · a GLP-1 receptor agonist · QST. I would like to set this up properly once, rather than adjust it repeatedly. My budget is real but not…